Astellas Pharma Inc. (ALPMY) Discusses R&D Strategy and Focus Areas in Innovative Healthcare - Slideshow

Astellas Pharma outlined its R&D strategy in April 2026, emphasizing quantum computing and AI-driven drug discovery to accelerate innovation in precision medicine and rare diseases. The company highlighted three core focus areas: gene therapy, regenerative medicine, and next-generation modalities like RNA-based treatments, leveraging quantum simulations for molecular optimization. Astellas plans to expand partnerships with quantum tech firms and academic institutions to integrate hybrid quantum-classical algorithms into early-stage drug design by 2028. Financial commitments include a 20% R&D budget increase, prioritizing quantum-enhanced computational biology to reduce clinical trial timelines by up to 30%. Executives stressed ethical AI and quantum governance frameworks, aiming to set industry standards for responsible deployment in healthcare innovation.